Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078477 | 0.89 | GCK (0.35) | MAPK14HPGDHDAC9GCKALDH1A1 | |
| SCHEMBL13870441 | 0.89 | HPGD (0.45) | MAPK14HPGDHDAC9GCKALDH1A1 | |
| SCHEMBL4079304 | 0.87 | PI4KA (0.39) | MAPK14HPGDHDAC9GCKALDH1A1 | |
| SCHEMBL4078512 | 0.86 | KDM4E (0.37) | HPGDALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL4075117 | 0.86 | MEN1 (0.43) | MAPK14HPGDHDAC9GCKPI4KA | |
| SCHEMBL2143887 | 0.86 | GCK (0.38) | MAPK14HDAC9GCKALDH1A1MAPT | |
| SCHEMBL13870458 | 0.84 | MAPK14 (0.36) | MAPK14HPGDHDAC9GCKALDH1A1 | |
| SCHEMBL13870489 | 0.83 | NPC1 (0.48) | MAPK14HPGDGCKALDH1A1KDM4E | |
| SCHEMBL13870481 | 0.79 | MAPT (0.41) | MAPK14ALDH1A1PI4KAPI4KBMAPT | |
| SCHEMBL2143855 | 0.78 | ADORA1 (0.40) | MAPK14HDAC9ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070238730-A1 | THIAZOLYL-DIHYDRO-CYCLOPENTAPYRAZOLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | claimed |
| US-7517995-B2 | Thiazolyl-dihydro-cyclopentapyrazole | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-14 | — | — | US | disclosed |
| US-20070238730-A1 | THIAZOLYL-DIHYDRO-CYCLOPENTAPYRAZOLE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238730-A1 | THIAZOLYL-DIHYDRO-CYCLOPENTAPYRAZOLE | REN, ROR1, RORB | MAPK14 3336/4885HPGD 1487/4885HDAC9 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.